EA201070636A1 - Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения - Google Patents

Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения

Info

Publication number
EA201070636A1
EA201070636A1 EA201070636A EA201070636A EA201070636A1 EA 201070636 A1 EA201070636 A1 EA 201070636A1 EA 201070636 A EA201070636 A EA 201070636A EA 201070636 A EA201070636 A EA 201070636A EA 201070636 A1 EA201070636 A1 EA 201070636A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ron
treatment
methods
inhibition
stimulating macrophage
Prior art date
Application number
EA201070636A
Other languages
English (en)
Other versions
EA018717B1 (ru
Inventor
Даниэль Перейра
Дженнифер О'Тул
Original Assignee
Имклоун Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364492&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Имклоун Элэлси filed Critical Имклоун Элэлси
Publication of EA201070636A1 publication Critical patent/EA201070636A1/ru
Publication of EA018717B1 publication Critical patent/EA018717B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Согласно настоящему изобретению предложены антитела или фрагменты антител, включая антитела человека, специфичные в отношении рецептора к белку, стимулирующему макрофаги (MSP-R или RON), которые подавляют активацию RON. Также предложены способы ингибирования RON, в частности применение RON для лечения таких заболеваний, как рак.
EA201070636A 2007-11-21 2008-11-21 Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение EA018717B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98955807P 2007-11-21 2007-11-21
PCT/US2008/013130 WO2009070294A2 (en) 2007-11-21 2008-11-21 Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof

Publications (2)

Publication Number Publication Date
EA201070636A1 true EA201070636A1 (ru) 2010-10-29
EA018717B1 EA018717B1 (ru) 2013-10-30

Family

ID=40364492

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070636A EA018717B1 (ru) 2007-11-21 2008-11-21 Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение

Country Status (20)

Country Link
US (2) US7947811B2 (ru)
EP (1) EP2222703A2 (ru)
JP (1) JP5324593B2 (ru)
KR (1) KR101227338B1 (ru)
CN (1) CN101868478B (ru)
AR (1) AR069393A1 (ru)
AU (1) AU2008330089B2 (ru)
BR (1) BRPI0820218A2 (ru)
CA (1) CA2706583A1 (ru)
CL (1) CL2008003449A1 (ru)
EA (1) EA018717B1 (ru)
IL (1) IL204743A (ru)
MX (1) MX2010005651A (ru)
NZ (1) NZ584271A (ru)
PA (1) PA8804901A1 (ru)
PE (1) PE20091713A1 (ru)
TW (1) TWI417106B (ru)
UA (1) UA99633C2 (ru)
UY (1) UY31478A1 (ru)
WO (1) WO2009070294A2 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014123A2 (en) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
JP2011509687A (ja) * 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｒｏｎ抗体およびその使用
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
SI2519543T1 (sl) * 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US8603478B2 (en) 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
RU2015125642A (ru) * 2012-11-30 2017-01-11 Дженентек, Инк. Композиции ron и способы их применения
RU2015140921A (ru) * 2013-02-26 2017-04-03 Роше Гликарт Аг Антитела к mcsp
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
KR20160014563A (ko) * 2014-07-29 2016-02-11 재단법인 아산사회복지재단 Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
WO2016036172A1 (ko) * 2014-09-03 2016-03-10 씨제이헬스케어 주식회사 단백질 키나제 억제제에 대한 감수성 예측용 바이오 마커 및 이의 용도
JP2020500834A (ja) * 2016-08-26 2020-01-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ マクロファージ刺激タンパク質受容体（又はＲＯＮ（Ｒｅｃｅｐｔｅｕｒ ｄ′Ｏｒｉｇｉｎｅ Ｎａｎｔａｉｓ））抗体及びその使用
WO2018052789A1 (en) 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
EP4214229A1 (en) * 2020-09-15 2023-07-26 Duke University Coronavirus antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE221915T1 (de) 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US20020103345A1 (en) * 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2004527456A (ja) 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
SE518548C2 (sv) 2001-04-11 2002-10-22 Sca Hygiene Prod Ab Absorberande alster med förbättrad diskretion
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) * 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
EP1622942B1 (en) 2003-05-01 2014-11-19 ImClone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1773881A4 (en) * 2004-05-13 2008-08-06 Imclone Systems Inc Inhibition of macrophage-stimulating protein receptor (RON)

Also Published As

Publication number Publication date
CN101868478A (zh) 2010-10-20
US7947811B2 (en) 2011-05-24
AU2008330089B2 (en) 2013-09-05
JP2011504176A (ja) 2011-02-03
US20110135631A1 (en) 2011-06-09
BRPI0820218A2 (pt) 2015-06-23
MX2010005651A (es) 2010-06-11
KR101227338B1 (ko) 2013-01-28
CN101868478B (zh) 2013-11-13
IL204743A (en) 2013-10-31
AU2008330089A1 (en) 2009-06-04
PA8804901A1 (es) 2009-06-23
PE20091713A1 (es) 2009-11-13
NZ584271A (en) 2012-05-25
UY31478A1 (es) 2009-07-17
US8133489B2 (en) 2012-03-13
UA99633C2 (ru) 2012-09-10
KR20100074293A (ko) 2010-07-01
WO2009070294A2 (en) 2009-06-04
TWI417106B (zh) 2013-12-01
CL2008003449A1 (es) 2010-02-19
CA2706583A1 (en) 2009-06-04
EA018717B1 (ru) 2013-10-30
AR069393A1 (es) 2010-01-20
IL204743A0 (en) 2010-11-30
JP5324593B2 (ja) 2013-10-23
TW200936161A (en) 2009-09-01
US20090136510A1 (en) 2009-05-28
EP2222703A2 (en) 2010-09-01
WO2009070294A3 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA201170155A1 (ru) Специфические антагонисты рецептора fgf-r4
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MX360497B (es) Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos.
MX2017001599A (es) Anticuerpos novedosos y sus usos.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
NZ590131A (en) Notch-binding agents and antagonists and methods of use thereof
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
ATE526987T1 (de) Dr5-antikörper und deren verwendung
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
EA200970738A1 (ru) Ингибиторы активности akt
NZ599875A (en) Human il-23 antigen binding proteins
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ RU